What is the primary requirement for a safe and effective dengue vaccine to avoid Antibody-Dependent Enhancement (ADE)?

It must be tetravalent, targeting all four DENV serotypes simultaneously.

It must be monovalent, targeting only the most prevalent serotype.

It must be a non-live vaccine to prevent any viral replication.

It must be administered only to individuals who have never contracted dengue.

In the context of the Qdenga vaccine trials, what does the term 'seronegative' refer to?

Individuals who have not been exposed to a natural dengue infection and lack specific antibodies.

Individuals who are immune to DENV-1 and DENV-2 but not DENV-3 or DENV-4.

Individuals who have developed severe dengue symptoms after a second infection.

Individuals who have been vaccinated against all four dengue serotypes.

Daily

250 words

6/10
Rating

28 July 2026

Dengue vaccine approval in India

The approval of a new vaccine for a major public health challenge like dengue is a significant development in medical science and technology that directly impacts India's public health policy.

Notes

India has approved Qdenga, the country's first dengue vaccine, manufactured by Takeda (Japan).
The vaccine is approved for individuals aged 4-60 years, regardless of prior dengue exposure.
Dengue virus has four distinct serotypes (DENV-1 to DENV-4); immunity to one does not guarantee protection against others.
Antibody-Dependent Enhancement (ADE): A phenomenon where antibodies from a primary infection can enhance the severity of a secondary infection by a different serotype.
An effective dengue vaccine must be 'tetravalent', targeting all four serotypes equally to prevent ADE.
Phase-3 clinical trial data (20,000 participants) showed an overall efficacy of approximately 80%.
Data indicates 'variable VE' (Vaccine Efficacy): Seronegative children vaccinated with Qdenga were 25% more likely to be infected by DENV-3 compared to unvaccinated children.
Efficacy against DENV-4 remains unknown due to insufficient data.
Researchers suggest that screening for prior dengue exposure (serostatus) before vaccination is necessary to mitigate risks for seronegative individuals.

Part of a longer story

This is day 4 of 5 in Approval of Qdenga dengue vaccine in India, which has been running since 21 July 2026. Reading it whole is usually worth more than reading today alone — the exam asks how something developed.

Questions

Discuss the challenges in developing a tetravalent dengue vaccine, specifically addressing the phenomenon of Antibody-Dependent Enhancement (ADE) and its implications for public health policy in India. 150 words

Attempt this — 150 words in 8 min

0 / 150 words 8:00
The introduction of new vaccines for endemic diseases requires a balance between rapid deployment and rigorous safety protocols. In the context of the recently approved dengue vaccine, analyze the necessity of serological screening prior to vaccination and the role of regulatory bodies in ensuring long-term safety monitoring. 250 words

Attempt this — 250 words in 11 min

0 / 250 words 11:00

Prelims

What is the primary requirement for a safe and effective dengue vaccine to avoid Antibody-Dependent Enhancement (ADE)?

In the context of the Qdenga vaccine trials, what does the term 'seronegative' refer to?

Syllabus

Achievements in science & technology: indigenization, new technology GS3

Topics

Sources

India’s first dengue vaccine arrives with a crucial safety caveat

250words.in · https://250words.in/daily/2026-07-28/dengue-vaccine-approval-in-india